Home » Stocks » SCYNEXIS


Stock Price: $7.27 USD 0.30 (4.30%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 71.84M
Revenue (ttm) 57,000
Net Income (ttm) -37.80M
Shares Out 98.81M
EPS (ttm) -5.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $7.27
Previous Close $6.97
Change ($) 0.30
Change (%) 4.30%
Day's Open 6.99
Day's Range 6.89 - 7.31
Day's Volume 87,609
52-Week Range 5.00 - 14.40

More Stats

Market Cap 71.84M
Enterprise Value 51.46M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 98.81M
Float 7.79M
EPS (basic) -5.9
EPS (diluted) -5.55
FCF / Share -4.69
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.64M
Short Ratio 2.25
Short % of Float 1.80%
Beta 1.69
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,260.28
PB Ratio 10.79
Revenue 57,000
Operating Income -49.54M
Net Income -37.80M
Free Cash Flow -45.68M
Net Cash 20.38M
Net Cash / Share 2.06
Gross Margin 212.28%
Operating Margin -86,908.77%
Profit Margin -66,322.80%
FCF Margin -80,138.60%
ROA -71.53%
ROE -425.12%
ROIC -135.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(436.45% upside)
Current: $7.27
Target: 39.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-52.92%0%0%0%-79.54%-92.55%0.12%-
Gross Profit0.
Operating Income-48.92-29.98-26.32-27.82-28.35-14.65-8.19-11.20
Net Income-53.71-12.47-25.06-29.99-32.62-4.23-30.46-11.48
Shares Outstanding5.614.392.671.901.220.570.030.03
Earnings Per Share-9.60-2.80-9.40-15.80-26.80-26.90-1,394.70-352.50
Operating Cash Flow-38.12-28.32-24.56-29.35-24.55-9.47-4.31-10.60
Capital Expenditures--0.57--0.03-0.59-0.70-0.43-0.36
Free Cash Flow-38.12-28.89-24.56-29.38-25.13-10.18-4.74-10.96
Cash & Equivalents48.6944.4943.8958.5946.9932.241.402.39
Total Debt14.8815.0814.6514.25--15.0026.44
Net Cash / Debt33.8029.4029.2444.3346.9932.24-13.60-24.06
Book Value12.9031.2321.4134.8241.9533.43-108-65.42
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name SCYNEXIS, Inc.
Country United States
Employees 27
CEO Marco Taglietti

Stock Information

Ticker Symbol SCYX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: SCYX
IPO Date May 2, 2014


SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.